BFLY

Over the past six months (April 2026 - October 2026), Butterfly Network's stock (BFLY) experienced a 1-year change of +302.6% and a 1-month change of +27.4% as of October 5, 2026. Key events include reporting strong Q1 2026 financial results with revenue above consensus and beating adjusted EBITDA guidance (April 30, 2026), appointing Caroll H. Neubauer to its Board (May 8, 2026), and a 33% stock jump in mid-June following commentary on Midjourney Medical's full-body ultrasound scanner incorporating Butterfly's technology (June 18, 2026). Other events include Aleph Neuro unveiling brain images using Butterfly's technology (June 25, 2026), expanding into Brazil (July 2, 2026), and reporting Q2 2026 results with better-than-anticipated adjusted EPS despite revenue falling short, leading to an optimistic full-year outlook (July 30, 2026). Recent partnerships include Merge Labs for brain-computer interfaces (September 1, 2026), Mendaera's Focalist™ System becoming compatible with Butterfly's technology (October 1, 2026), and Bridge Neurotech for non-invasive brain-computer interfaces (October 6, 2026). The company also appointed Mike Noonen to its Board (October 5, 2026) and is scheduled to report Q3 2026 results on October 29, 2026. Analyst sentiment is moderately bullish, with a consensus 'Moderate Buy' rating and price targets ranging from $10.00 to $15.00.